Objective: To assess whether CD8 þ T-cell activation predicts risk of AIDS and non-AIDS morbidity during suppressive antiretroviral treatment (ART).
Introduction
Despite the many effective treatment options currently available for participants with HIV infection, AIDSdefining events still cause hospitalizations and deaths, even among participants on suppressive antiretroviral treatment (ART) [1] . In addition, HIV-infected participants are at higher risk for serious morbidity and death due to nonopportunistic diseases, such as liver, cardiovascular, renal, and malignancies, than the general population [2, 3] . To inform the decision on which patients to institute additional treatments and preventive measures, it is important to identify patients with poor prognoses despite viral suppression with ART.
Several soluble markers of inflammation and coagulation have been associated with the risk of developing AIDS and non-AIDS morbidity during ART. In the Strategies for Management of Anti-Retroviral Therapy study, which randomized participants to continuous ART or intermittent CD4 þ T-cell count (CD4 cell count)-driven ART, soluble plasma markers of inflammation, monocyte activation, and coagulation [high-sensitivity C-reactive protein (hsCRP), interleukin-6, sCD14, and D-dimer] predicted subsequent all-cause mortality; importantly, this effect was also observed in the subset of individuals randomized to continuous ART [4, 5] . Similar associations have been observed in Fat Redistribution and Metabolic Change in HIV infection [6] , Evaluation of Subcutaneous Proleukin in a Randomized International Trial [7] , Veterans Aging Cohort Study [8] , and Flexible Initial Retrovirus Suppression Therapies studies [9] . However, none of these studies evaluated the prognostic significance of T-cell activation during ART-mediated viral suppression.
T-cell activation has been used as the primary surrogate outcome for several recent randomized controlled trials of immune-based interventions in this setting [10] [11] [12] , given its superior stability and reproducibility within individuals, but it may reflect distinct pathophysiologic pathways from markers of inflammation and monocyte activation. Most of the larger cohorts with sufficient numbers of events to assess morbidity and mortality have focused on measurements that can be performed with stored plasma. These soluble biomarkers generally reflect activation of the innate immune and coagulation systems. The study of T-cell activation and function requires access to cryopreserved cells and is logistically more challenging. T-cell activation -as defined by co-expression of human leukocyte antigen (HLA)-DR and CD38 -fails to normalize during effective ART [13] [14] [15] . The frequency of these cells in untreated HIV disease is a well established biomarker of disease progression [16, 17] . However, the prognostic significance of these cells during suppressive ART has been less well defined. Smurzynski et al. [1] reported that higher pretreatment CD8 þ T-cell activation (%CD38/HLA-DR þ ) was significantly associated with a subsequent AIDS diagnosis, although the effect was attenuated after adjustment for pretreatment HIV-RNA and CD4 cell count, and the prognostic significance of these markers during early viral suppression was not assessed. Hunt et al. found that higher CD8 þ T-cell activation during early ART-mediated viral suppression predicted subsequent mortality in a relatively small Ugandan cohort (n ¼ 10 deaths, [18] ), and in the larger Study of the Ocular Complications of AIDS (SOCA) cohort of North Americans with a history of AIDS (n ¼ 64 deaths, [19] ), but not in the smaller SCOPE cohort with less advanced disease stage (n ¼ 27 deaths, [19] ). Hence, the role of T-cell activation as a predictor of disease progression during ART remains unclear.
Modern ART regimens are very effective at indefinitely suppressing HIV replication. Hence, the field is now focused on defining the nature of residual disease during suppressive ART. In our current analysis, we assess the impact of CD8 þ T-cell activation and CD4 cell count measured 1 year after ART initiation on the probability of clinical events in years 2-5 of ART, had everyone maintained ART-mediated viral suppression. Recognizing that even with modern ART, sustained virologic suppression is not achievable for all patients, we also performed an 'on-treatment' analysis using previously published methods [20, 21] . Given the associations between aging, inflammation and morbidity in the general population, we also investigated the association between T-cell activation and morbidity/mortality in older individuals.
Methods

Population
We used data from randomized treatment studies including ART-naive patients ('parent'studies) conducted by the AIDS Clinical Trials Group (ACTG): ACTG protocols 384 [22, 23] , 388 [24] , A5014 [25] , and A5095 [26] . We restricted the analysis to the 1036 participants who were virologically suppressed (HIV-RNA 200 copies/ml) at week 48 or 64 after ART initiation ('year 1'), and who had data on CD8 þ T-cell activation at that time. All these patients lived in the United States. Most (941, 91%) of these participants also enrolled in the ACTG's long-term observational study AIDS Clinical Trials Group Longitudinal Linked Randomized Trials protocol (ALLRT) [27] , which provides standardized long-term follow-up after completion of parent studies. Patients were invited to enroll into the parent studies and ALLRT by their physicians. ALLRT did not provide treatment. At the time of analysis, all participants had potential follow-up of 5 years after ART initiation. We excluded the 11 participants with an event occurring within 12 weeks prior to the year-1 CD8 þ T-cell activation measurement because the level of immune activation could be affected by the previous event.
Evaluations for these studies continued regardless of changes in or discontinuation of ART. Participants provided written informed consent for participation in these studies. All participating sites received institutional review board approval for the studies.
Outcomes AIDS-defining events were as defined by the Centers for Disease Control [28] and identified as previously described [1] . Non-AIDS-defining events were defined by the methods used in earlier ACTG analyses [29] . The primary outcome was the occurrence of any of the following events in years 2-5 after ART initiation: AIDSdefining event, nonaccidental death, hepatic end-organ disease (including ascites, esophageal/gastric varices, hepatic encephalopathy), cardiovascular end-organ disease (including myocardial infarction, stroke, coronary artery intervention, pulmonary embolism, thrombosis), serious renal disease (including confirmed estimated glomerular filtration rate < 60 ml/min per 1.73 m 2 using the Modification of Diet in Renal Disease equation for estimated glomerular filtration rate at least 3 months apart), non-AIDS cancers, hip, spine or wrist fractures, diabetes mellitus, and serious bacterial infections (including pneumonia, bacteremia, meningitis, sepsis).
Loss-to-follow-up
Loss-to-follow-up was defined as the earliest of 6 months after the last HIV-RNA measurement, or after 6 months without HIV-RNA measurement.
Laboratory measurements
The percentage of CD8 þ T-cells co-expressing CD38 þ / HLA-DR þ (CD8 þ T-cell activation) was measured on fresh blood using an ACTG consensus protocol at multiple laboratories. HIV-RNA quantification was performed using the Roche Amplicor assay v1.0 or v1.5 (Roche Diagnostic Systems, Branchburg, New Jersey, USA). CD4 cell count and HIV-RNA measurements were collected every 8 or 16 weeks.
Statistical analyses
We estimated the probability of experiencing a clinical event in years 2-5 had a participant remained on suppressive ART, dependent on certain prognostic factors. Prognostic factors considered were year-1 CD8 þ T-cell activation and square root of year-1 CD4 cell count. Additional covariates included in univariate models were age, sex, history of IDU, randomized study, square root of pre-ART CD4 cell count, pre-ART log 10 viral load, year-1 naive CD4 percentage, and the occurrence of an event in year 1. Multivariable models included variables that had a P-value less than 0.10 in univariate analyses and year-1 CD8 þ T-cell activation. Because of current scientific knowledge, we also fit models with pre-ART and year-1 CD4 cell count.
All probabilities and odds ratios (ORs) were estimated for the complete population of 1025 participants. We censored participants after they interrupted ART for more than 21 days and at confirmed virologic failure, using a confirmed more than 200 copies/ml threshold [30] . We then estimated the probability of events with a logistic regression model, using inverse probability of censoring weighting (IPCW) to address informative censoring [20, 31, 32] . This approach estimates outcomes in the entire study population, including those subsequently lost-to-follow-up, rather than describing a subgroup selected over time. In practice, the unobserved outcomes of participants who were lost-to-follow-up/off-suppressive-ART are represented by increasing the weight given to the outcomes of 'similar' uncensored participants.
The weights are obtained from the probability of remaining in follow-up/on suppressive ART at a given time in terms of past observed covariate values (these covariates are the basis for identifying 'similar' participants). We used separate logistic regression models, pooled over the time points, for remaining in follow-up and having ART-induced viral suppression. We divided the data into 28-day periods, with covariates measured at the end of each period [33] , carrying values forward until the covariate was measured again.
The variables included in the pooled logistic models for both types of censoring, lost-to-follow-up and offsuppressive-ART, were covariates thought to be predictive of both censoring and clinical events [32] . Based on prior findings [20, 34] , we included age, sex, history of IDU, pre-ART log 10 viral load, year-1 CD8 þ T-cell activation, square root of CD4 cell count (time-dependent), viral load 50 or less (time-dependent), period and period squared, and study stage. Study stage was a categorical variable indicating within-parent study, end-of-parent study, or within-ALLRT. If significant, we also included age squared. Confidence intervals were obtained by bootstrap [31] , using Efron's percentile method [35] .
In sensitivity analyses, we performed stepwise model selection, starting with the above covariates and also including white race, parent study, and square root of baseline CD4 cell count, and forcing year-1 CD8 þ T-cell activation and period in the model. We also investigated sensitivity of our results to excluding participants with events within 12 weeks before year 1: excluding participants with events within 6 months, and not excluding participants. Results (not shown) changed minimally. SAS 9.1.3 (SAS Institute Inc., Cary, North Carolina, USA) was used for all analyses.
Results
A total of 1025 participants were included in our analyses ( Table 1) . Among all 1025 participants, 114 had an event in years 2-5. For the hypothetical scenario had everyone remained on suppressive ART, 379 participants maintained ART-mediated viral suppression (no confirmed HIV-RNA >200 copies/ml) through year 5 or until they had a clinical event (uncensored). The 646 censored participants stopped drugs (n ¼ 216, 33%), had confirmed virologic failure (n ¼ 178, 28%), or were off follow-up or did not have viral load measurements for 6 months (n ¼ 252, 39%). In participants censored because of confirmed virologic failure, median time between year-1 measurement and confirmed virologic failure was 9 months.
For the multivariable IPCW censoring models, no IDU and a higher current CD4 cell count were associated with a higher probability of remaining in follow-up for participants maintaining persistent virus control. The effect of age in this model was nonlinear. Younger age, history of IDU, higher year-1 CD8 þ T-cell activation, higher current CD4 cell count, and current HIV-RNA above 50 copies/ml were significantly associated with a higher probability of the combined censoring endpoint of virologic failure and ART discontinuation.
Ninety-four of the 379 uncensored participants had at least one event. Of the first events, 12 were AIDSdefining and 82 non-AIDS-defining. In participants who were virologically suppressed and had CD8 þ T-cell activation data at year 1, the overall estimated probability of clinical events in years 2-5 was 13% (95% CI 10%-15%), had these participants maintained ART-mediated viral suppression. The risk per year decreased slightly over years 2-5.
Year-1 CD8 þ T-cell activation was a significant predictor of the probability of an event in years 2-5, with an OR of 1.22 for each 10% higher activated CD8 þ T cells (P ¼ 0.02, Table 2 ), had everyone remained on ART and suppressed. This relationship was also seen after adjustment for pre-ART and year-1 CD4 cell counts. However, adjusting for age attenuated the OR of CD8 þ T-cell activation to 1.11 (95% CI 0.94-1.32). Age was a significant predictor of clinical events in all three models that included age; in multivariable model C (Table 2) , the OR of a clinical event was 2.13 (95% CI 1.62-2.87, P < 0.0001) for each 10-year older age. Neither year-1 CD8 þ T-cell activation nor year-1 CD4 cell count was significant in the multivariable model that included age. Age positively correlated with year-1 CD8 þ T-cell activation (P < 0.0001), but with a proportion of explained variation of only 0.03. Table 3 summarizes the dependence of clinical events on year-1 CD8 þ T-cell activation and age. Inferences were unchanged in the on-treatment analysis, which included follow-up while participants exhibited virologic failure despite continuing ART (Table 4 ).
In an exploratory analysis of the effect of the absolute number of activated CD8 þ T cells on the probability of clinical events, for every 100 cells/ml higher activated CD8 þ T cells, the OR was 1.16 (95% CI 1.04-1.31, P ¼ 0.01). When adjusted for age, the OR was attenuated to 1.13 (95% CI 0.97-1.23, P ¼ 0.096). 
Impact of CD8 R T-cell activation in participants age at least 50 years
In an exploratory analysis we also investigated the effect of CD8 þ T-cell activation in the 108 participants age at least 50 years [median age 55, interquartile range (52-59)]. We chose the cutoff of 50 as this has been commonly used to define 'older' in other HIV cohorts. Of 56 uncensored participants, 27 had an event. The overall probability of events in participants at least 50 years in years 2-5 had everyone remained on suppressive ARTwas 37% (95% CI 24-48%). In participants at least 50 years, the OR of a clinical event was 1.42 (95% CI 1.07-2.47, P ¼ 0.015) for each 10% higher CD8 þ T-cell activation ( Table 5 ). This relationship remained significant when adjusted for age: OR 1.43 (95% CI 1.06-2.64, P ¼ 0.018). Although the relationship between CD8 þ T-cell activation and clinical events appeared to be stronger in the subgroup of participants age at least 50 years, we did not find significant evidence of interaction by age (P ¼ 0.45, for age continuous).
Impact of CD8 R T-cell activation on non-AIDS-defining events and death
We next evaluated the risk of non-AIDS-defining events and death, had everyone remained on suppressive ART. For this analysis, of 374 uncensored participants, 85 had a non-AIDS-defining event or died. 
Discussion
Even had all individuals maintained optimal virologic response to therapy, an excess risk of non-AIDS morbidity exists in participants who were virologically suppressed after 1 year of ART. In addition to low-level HIV replication, this excess risk may be due to multiple nonvirologic factors, including traditional risk factors (e.g., substance use), ART toxicity and persistent immune dysfunction/inflammation. Serious non-AIDS-defining events cause much more of this disease burden than AIDS-defining events.
Given the prognostic utility of CD8 þ T-cell activation in untreated HIV disease, we analyzed the role of CD8 þ Tcell activation in a well characterized cohort of long-term treated adults enrolled in a clinical trials network. We used IPCW to estimate the risk of disease progression had no one in the cohort experienced confirmed virologic failure or treatment interruptions longer than 21 days, as the vast majority of participants in modern clinic cohorts appear to now routinely achieve this outcome and this is the group for which immune-based interventions are likely to be used [36] .
We found that the frequency of cells expressing CD38 and HLA-DR on CD8 þ T cells (which have long been considered 'activated') measured at year-1 of ARTmediated viral suppression predicted an increased risk of subsequent AIDS and non-AIDS events in years 2-5, had everyone remained on suppressive ART. Adjustment for age attenuated the prognostic effect of CD8 þ T-cell activation.
These results reach a somewhat different conclusion than the Ugandan study [18] and the SOCA cohort [19] . However, the Ugandan study had many fewer events, and the SOCA cohort had uniformly low pre-ART CD4 cell counts.
We found a statistically significant association between age and CD8 þ T-cell activation in this cohort, which is generally consistent with findings that many markers of inflammation correlate with age in the general population, as well as in HIV-infected individuals suppressed on ART [3, 37] . However, the proportion of variation explained by age was only 0.03.
Most studies finding a link between inflammation and disease progression in the general population focused either on the very old [38, 39] or on individuals who were at high risk for developing complications (e.g., adults who had acute coronary syndrome [40] ). Because it has been used in other HIV cohorts, we defined 'older' in this cohort as anyone age 50 years and older. In this group of individuals who had excess comorbid conditions and a much higher risk for disease progression, we found a significant effect of CD8 þ T-cell activation that remained 2106 AIDS 2013, Vol 27 No 13 Table 3 . Estimated probabilities of an event in years 2-5 had everyone remained on antiretroviral treatment and suppressed.
Age at year 1 CD8 þ T-cell activation percentage at year 1   10  20  30  40  50   2 5  3  4  4  5  5  3 0  5  5  6  7  7  3 5  7  8  9  9  1 0  40  10  11  12  13  14  45  14  15  16  18  20  50  19  20  22  24  26  55  25  27  29  31  34 Data on table are presented in percentages. The conclusions are based on logit link for age and year-1 CD8 þ T-cell activation percentage. The authors did not include pre-antiretroviral treatment or year-1 CD4 cell count because these effects were not significant and the point estimate indicated that higher CD4 cell count was harmful, countering the current scientific knowledge. unchanged even after adjusting for age. Although we did not detect statistically significant interaction by age, this subset analysis is consistent with the hypothesis that immune activation is a more important driver of disease risk in older participants. Based on the geriatrics literature, one might expect inflammation to be more important in the elderly. This may simply be a power issue (older participants experience more events), but it is also possible that inflammation and immune activation is a more important mediator of disease risk in this population and interventions might be best targeted in this group [29, 40] . Many inflammatory markers -including CRP, interleukin-6 and tumor necrosis factor-a -increase with age [41] . This increase is present even in healthy, older individuals and does not appear to be driven by increased frequency of acute infections. Although it remains unknown whether the increased inflammatory burden in the elderly is a cause or consequence of other comorbid conditions, the consistent observation that inflammation predicts multiple age-associated diseases such as coronary artery disease, cancer, sarcopenia (loss of muscle mass and poor muscle function, typical of older age), frailty and osteoporosis, suggests that chronic inflammation is integral to the aging process and that the prognostic significance of inflammatory biomarkers might be more apparent in older individuals.
It is also important to note that even in the subset of older participants, where CD8 þ T-cell activation appeared to independently predict morbidity and mortality, the association was relatively modest. Much stronger associations have been observed between markers of inflammation (i.e., interleukin-6, hsCRP, fibrinogen), monocyte activation (sCD14), and coagulation (D-dimer) and clinical events during treated HIV infection [4] [5] [6] [7] [8] [9] . CD8 þ T-cell activation may reflect an aspect of pathogenesis that is less closely related to the proximal immunologic events mediating the risk of disease in treated HIV infection than markers of inflammation, monocyte activation, and coagulation. However, more research is needed to better understand the biologic mechanisms contributing to CD8 þ T-cell activation in well suppressed individuals on ART, and the connections to cytokines such as interleukin-6. This may have important implications for identifying targets for novel interventions.
The pretherapy and on-therapy CD4 þ T-cell count has been a consistent predictor of disease progression in many other cohorts. We were surprised to find in our analysis that neither pre-ART CD4 cell count nor year-1 CD4 cell count were significantly associated with clinical events. This may be related to the fact that most (87%) of the first events after year 1 were non-AIDS-defining. In addition to renal events, only a small number of non-AIDS-defining cancers have been shown to have a relationship with CD4 cell count. Predicting events after the first year of ARTalso largely excludes clinical events that may have been related to immune reconstitution inflammatory syndromes, which are typically associated with lower pre-ART CD4 cell counts. Also, the limited effect of a higher CD4 cell count may be due to our focus on the scenario had everyone remained on (suppressive) ART. For example, the analysis in [42] did not restrict to HIV-RNA suppression, and so the low time-updated CD4 cell counts in their analysis that were associated with the risk of non-AIDS cancers may have been confounded with lack of viral suppression. These issues may also play a role in attenuating the predictive value of CD8 þ T-cell activation.
A strength of this study is the prospective cohort design, allowing both unadjusted and adjusted analyses. Another strength is the standardized data collection of all the necessary variables. In addition, our analyses have used IPCW to deal with possibly informative censoring, especially important when censoring participants when they go off (suppressive) ART.
Given our sample size, we could not rule out an ageadjusted OR as high as 1.32 among all participants. In addition, we have inadequate statistical power to look at the effect of CD8 þ T-cell activation on events of a specific type. Another limitation is the fact that T-cell activation was measured in different laboratories in our study (i.e. measurement error), although an ACTG consensus protocol was used by all laboratories. Due to the number 2108 AIDS 2013, Vol 27 No 13 of laboratories, we did not have sufficient power to further investigate this. In addition, there may have been residual measured or unmeasured confounding, which we have not corrected for by IPCW.
To summarize, CD8 þ T-cell activation is prognostic for clinical events during effective ART, but this association is largely confounded by age, and is smaller in magnitude than those recently reported for markers of innate immune activation, inflammation, and coagulation. Older HIVinfected individuals are at significantly higher risk of clinical events than younger patients. The significant and independent association between CD8 þ T-cell activation and clinical events in participants age 50 years and older suggests that HIV-associated immune activation may be a more important driver of disease in this population, although this hypothesis needs to be confirmed in future studies. Another reasonable explanation is that excess morbidity in older individuals may be causing inflammation even before the clinical event is diagnosed, and that our ability to detect this association is greater in moreaffected older adults. However, the latter seems less likely since CD8 þ T-cell activation at year 1 had similar prognostic capacity for events occurring after year 2 (see footnotes of Tables 2 and 5 ). The fact that CD8 þ T-cell activation appears to be less predictive of clinical events than previously reported inflammatory markers may suggest that interventions specifically targeting innate immune activation and its determinants may hold more promise than interventions specifically designed to decrease CD8 þ T-cell activation during treated HIV infection.
A related article, focusing on statistical methods but using the same data, was presented by Judith Lok at ICSA, Boston, June 2012: 'Careful selection of surrogate outcomes with application to predictors of clinical events in HIV-positive patients' (invited talk). The submitted article has been presented at CROI, Atlanta, March 2013: 'The Prognostic Capacity of CD8 þ T Cell Activation During Effective Antiretroviral Therapy (ART) Is Attenuated By Age'. 
